ArticleJournal of nanobiotechnology2026
Oral microalgal nanoparticle hydrogel for multifaceted management of chronic oral ulcers in diabetes.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The treatment of chronic oral ulcer healing, particularly in diabetic patients, presents a significant clinical challenge. Current therapeutic strategies have inadequately addressed the complexities associated with diabetic oral ulcers, underscoring the urgent need for innovative solutions. In this study, nanoparticles were extracted from edible spirulina powder (SP-NPs) and incorporated into adhesive chitosan-based oral gel (CSgel), resulting in the development of an advanced functional hydrogel (SP-NPs@CSgel) designed to manage chronic oral ulcers in diabetes. The SP-NPs, rich in proteins involved in antioxidant and anti-inflammatory processes, demonstrated significant potential in repairing cellular damage by mitigating oxidative stress and modulating inflammation through the inhibition of the NF-κB pathway in macrophages, with the percentage of M2 macrophage increasing to 27% versus merely 12% in the control group. Additionally, the CSgel exhibited excellent injectable and adhesive properties, which prolonged the retention of SP-NPs in the oral mucosa for over 8 h, representing a four-fold increase compared to merely 2 h for free SP-NPs, thereby significantly accelerating the healing of chronic oral ulcers with complete wound closure achieved within 8 days in diabetic rats and 14 days in diabetic mice with severe ulcers. Furthermore, the SP-NPs@CSgel showed promising effects in alleviating depression-related behaviors and regulating the oral microbiota in severe oral ulcers, creating a conducive environment for ulcer healing. In conclusion, by harnessing the synergistic effects of edible SP-NPs and adhesive CSgel, this hydrogel system represents a safe and effective approach with substantial potential for clinical transformation, offering a promising solution for chronic oral ulcer management in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.